Lynk Pharmaceuticals Reports P-II Clinical Trial Results of LNK01001 for the Treatment of Ankylosing Spondylitis
Shots:
- The P-II trial evaluating LNK01001 (high & low-dose) vs PBO in a ratio (1:1:1) in 177 patients who had an inadequate response to NSAIDs or were NSAID-intolerant. Professor Xiaofeng Zeng led the study
- The preliminary efficacy data showed a significant difference in the proportion of patients who achieved an ASAS40 response across high & low-dose groups after 12wks. Improvement in other efficacy indicators was consistent with the 1EPs
- LNK01001 showed a rapid onset of action with response rates for various efficacy EPs in both groups offering varying degrees of improvement starting from the 2nd wk. Both dose groups showed good overall safety & tolerability, treatment discontinuation due to AEs, serious AEs were low and comparable to PBO groups
Ref: PR Newswire | Image: Lynk Pharmaceuticals
Related News:- Zydus Group Reports Real-World Study Results of Exemptia (biosimilar, adalimumab) for Ankylosing Spondylitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
